-
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
04 Apr 2025 11:00 GMT
… antidepressant medicines called SSRIs or SNRIs. Stop taking SYMBRAVO and call your doctor … -12 AXS-12 (reboxetine) is a highly … and Drug Administration (FDA) Orphan Drug Designation for the treatment of … clinical trials and anticipated clinical trials for …
-
Experts pinpoint FIVE common medications that could raise dementia risk by up to 125%
21 Jan 2025 13:00 GMT
… diabetes medications, vitamins and supplements and antidepressants as … treatment.
Certain vaccines, antimicrobial treatments, anti-inflammatories and drugs …
'Clinical trials will help to answer …
ranitidine
rasagiline
reboxetine
rectal laxatives
renal failure …
-
Deadly side effects being 'hidden' from patients by drug firms - as scientists discover yet another harm of Ozempic
21 Jan 2025 11:00 GMT
… drugs.
The MHRA, which overseas the safety of medicines and vaccines, … all safety and trial data from pharmaceutical companies.
MPs … data that showed the antidepressant reboxetine was no more … asks doctors and pateients to report side effects of drugs, …
-
Narcolepsy Treatment AXS-12 Achieves Primary Endpoint in Long-Term Phase 3 Trial
27 Nov 2024 18:57 GMT
… Center at the Montefiore Medical Center and professor of … Evaluating Continued Treatment with Reboxetine)—a multicenter phase 3 trial that consisted … in three positive controlled trials, and indicate that the … Axsome's narcolepsy drug on fast track for …
-
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
26 Nov 2024 12:00 GMT
… at the Montefiore Medical Center and Professor … in three positive controlled trials, and indicate that … Treatment with Reboxetine) was a multicenter Phase 3 trial consisting … and Drug Administration (FDA) Orphan Drug Designation for the treatment of …
-
With narcolepsy trial win, Axsome looks to revive former Pfizer antidepressant on the US market
27 Nov 2024 15:59 GMT
… treatment that never made it to the U.S. market, reboxetine … phase 3 ENCORE trial measured the drug’s effect … -selling Xyrem and Avadel Pharmaceuticals’ newer entrant Lumryz. … called the antidepressant “ineffective and potentially harmful.” The medicine was …
-
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
26 Nov 2024 12:27 GMT
… at the Montefiore Medical Center and Professor … in three positive controlled trials, and indicate that … Treatment with Reboxetine) was a multicenter Phase 3 trial consisting … and Drug Administration (FDA) Orphan Drug Designation for the treatment of …
-
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
25 Jul 2024 12:30 GMT
… treatment market involves prescription drugs and non-prescription remedies … drugs like antidepressants, pain relievers and anti-seizure medications … biotech, pharma companies in the markets this week include: Tonix Pharmaceuticals … enantiomer of reboxetine, is …
-
The Latest on the Medications and Therapies That Treat Depression
15 Jul 2024 17:40 GMT
… line treatments for depression consist of antidepressant medications and … of randomized clinical trials, Simon et al … (Anafranil), vortioxetine (Brintellix), reboxetine (Edronax), and trazodone ( … borderline personality disorder, drug withdrawal, post-traumatic …
-
Differences in Long-Term Response Among Antidepressants for MDD
12 Jun 2024 20:00 GMT
… out that clinical trials of antidepressants are commonly … guidelines stating that sertraline had fewer drug interactions, … effective; fluoxetine, fluvoxamine, reboxetine, and trazadone were the … of 21 antidepressant drugs for the acute treatment of adults …